OPKO Health, Inc. (OPK)
| Market Cap | 1.25B +13.0% |
| Revenue (ttm) | 587.90M -11.5% |
| Net Income | -72.89M |
| EPS | -0.09 |
| Shares Out | 746.33M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,344,172 |
| Open | 1.620 |
| Previous Close | 1.620 |
| Day's Range | 1.610 - 1.680 |
| 52-Week Range | 0.977 - 1.730 |
| Beta | 1.50 |
| Analysts | Buy |
| Price Target | 4.38 (+162.28%) |
| Earnings Date | Oct 28, 2026 |
About OPK
OPKO Health, Inc. operates as a healthcare company, in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company operates in two segments, Pharmaceutical and Diagnostics. The Pharmaceutical segment develops MDX2001, a tetra-specific antibody targeting several types of solid tumors in Phase 1 clinical trials; MDX2003, a tetra-specific antibody targeting two antigens for hematological tumors in Phase 1 clinical trials; and MDX2004, a trispecific immune modulator to rebuild and sustain the patient's own immune syst... [Read more]
Financial Performance
In 2025, OPKO Health's revenue was $606.88 million, a decrease of -14.90% compared to the previous year's $713.14 million. Losses were -$225.68 million, 324.0% more than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for OPK stock is "Buy." The 12-month stock price target is $4.38, which is an increase of 162.28% from the latest price.
News
OPKO Health Transcript: Wells Fargo 21st Annual Healthcare Conference
The company is shifting from diagnostics to therapeutics, highlighted by ModeX’s multi-specific antibody platform and a robust clinical pipeline. Strategic collaborations with Merck and Regeneron, strong capital position, and active shareholder returns support growth, with several clinical milestones expected in the next 12–18 months.
OPKO Health to Participate in the Wells Fargo 21st Annual Healthcare Conference
MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across established...
OPKO Health Expands Strategic Relationship with HealthCare Royalty Through $125 Million Notes Issuance Secured by Mazdutide Royalty Interests
Transaction provides additional non-dilutive capital and enhanced financial flexibility while preserving meaningful long-term royalty upside Transaction provides additional non-dilutive capital and en...
Cocrystal Pharma announces $5M investment from Opko Health
Cocrystal Pharma (COCP) announced a $5M investment from Opko Health (OPK) as the company advances its lead norovirus program toward Phase 1b topline data later this year. Under the terms…
Cocrystal Pharma announces $5M private placement with Opko Health
Cocrystal Pharma (COCP) announced a $5M investment from OPKO Health (OPK), a longtime investor in the company. Under the terms of the agreement, Cocrystal sold 5,474,053 shares of its common…
Opko Health sees Q3 revenue $131M-$142M, consensus $134.65M
Sees Q3 total costs and expenses $180M-$190M, with R&D expenses projected at $34M-$38M.
Opko Health sees FY26 revenue $560M-$585M, consensus $536.88M
Sees FY26 total costs and expenses $710M-$740M.
Opko Health reports Q2 EPS (1c), one estimate (11c)
Reports Q2 revenue $163.5M, consensus $131.23M. Reports Q2 pharmaceutical revenue rose to $89M, driven by higher sales volumes in Spain and Mexico and $29.4M recognized from an amended license agreeme...
OPKO Health Earnings Call Transcript: Q2 2026
Q2 2026 saw improved profitability, strong cash reserves, and pipeline progress, with revenue rising to $163.6M and operating loss narrowing to $7M. Diagnostics and pharma segments both improved, while guidance for 2026 was raised on the back of robust product and partnership revenue.
OPKO Health Earnings release: Q2 2026
OPKO Health released its Q2 2026 earnings on July 27, 2026, summarizing the period's financial results.
OPKO Health Quarterly report: Q2 2026
OPKO Health has published its Q2 2026 quarterly earnings report on July 27, 2026.
OPKO Health Reports Second Quarter 2026 Business Highlights and Financial Results
MIAMI, July 27, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across estab...
OPKO Health to Report Second Quarter 2026 Financial Results on July 27, 2026
MIAMI, July 23, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (OPKO) (NASDAQ: OPK), a fully-integrated healthcare company focused on delivering next-generation solutions for serious diseases across estab...
OPKO Health Transcript: AGM 2026
The meeting approved all board proposals, including director elections and the 2026 equity plan. Key business updates highlighted clinical pipeline progress, asset sales, and strong cash flow from royalties and diagnostics. $98 million remains authorized for share repurchases.
Entera Bio and Opko Health present preclinical data for oral peptides
Entera Bio (ENTX) and Opko Health (OPK) reported preclinical data at the ENDO 2026 annual meeting for their co-developed EB612 and EB618 oral peptide programs. For EB612, a long-acting oral…
Preclinical Data for OPKO Biologics' OPK8801001 in Acromegaly Presented at ENDO 2026
MIAMI, June 15, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) OPKO Biologics, an OPKO Health company, presented preclinical data for OPK8801001 at ENDO 2026, the Endocrine Society's annual ...
OPKO Health Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing a robust pipeline of multispecific antibodies and in vivo CAR T therapies, with key data updates expected for MDX-2001, the Merck EBV vaccine, and a SARS antibody program in the next 6-12 months. Global clinical expansion and strategic collaborations are driving innovation and growth.
OPKO Health Proxy statement: Proxy filing
OPKO Health filed a proxy statement on May 15, 2026, providing details for shareholder voting and corporate governance matters.
OPKO Health's ModeX Therapeutics Will Present Data Demonstrating In Vivo CAR-T Cell Generation and Deep B-Cell Depletion in Preclinical Studies
Multispecific antibody conjugated LNP/mRNA platform enables in vivo T-cell engineering and systemic B-cell depletion in animal models Data will be presented at the American Society of Gene & Cell The...
OPKO Health Slides: Corporate presentation
OPKO Health has posted slides in relation to its latest quarterly earnings report, which was published on May 8, 2026.
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China
MIAMI, April 30, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) today announced that its subsidiary EirGen Pharma Limited (EirGen) has entered into an amendment to its agreement with ...
BioReference® Launches BioReference Direct™, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform
ELMWOOD PARK, N.J., April 30, 2026 (GLOBE NEWSWIRE) -- BioReference® Health LLC, an OPKO Health, Inc. company and a trusted provider of diagnostic testing in the United States, today announced the lau...
OPKO Health Proxy statement: Proxy filing
OPKO Health filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
OPKO Health Proxy statement: Proxy filing
OPKO Health filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
Opko Health downgraded to Market Perform from Outperform at Barrington
Barrington analyst Michael Petusky downgraded Opko Health (OPK) to Market Perform from Outperform with no price target The firm previously had expected BRH break-even or profitability in 2026 and now…